Haematological Effects of Interferon-β-1a (Rebif ® ) Therapy in Multiple Sclerosis

ISSN： 0114-5916

Source： Drug Safety, Vol.27, Iss.10, 2004-01, pp. : 745-756

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Subcutaneous Recombinant Interferon-β-1a (Rebif®): A Review of its Use in the Treatment of Relapsing Multiple Sclerosis

By Sanford Mark Lyseng-Williamson Katherine A.

Drugs, Vol. 71, Iss. 14, 2011-10 ,pp. : 1865-1891

Adis International

Access to resources Recommend Favorite

Development of interferon-β as a therapy for multiple sclerosis

By Markowitz Clyde

Expert Opinion on Emerging Drugs, Vol. 9, Iss. 2, 2004-11 ,pp. : 363-374

Informa Healthcare

Access to resources Recommend Favorite

Interferon-β_1b for the treatment of multiple sclerosis

By Lam Sum Wang Shan Gottesman Malcolm

Expert Opinion on Drug Metabolism and Toxicology, Vol. 4, Iss. 8, 2008-08 ,pp. : 1111-1117

Informa Healthcare

Access to resources Recommend Favorite

Interferon-β_1b in the treatment of multiple sclerosis

By Río Jordi Montalban Xavier

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 16, 2005-12 ,pp. : 2877-2886

Informa Healthcare

Access to resources Recommend Favorite

Improving Compliance with Interferon-β Therapy in Patients with Multiple Sclerosis

By Portaccio Emilio >

CNS Drugs, Vol. 23, Iss. 6, 2009-05 ,pp. : 453-462

Adis International

Access to resources Recommend Favorite